ADVA
14.7.2020 09:02:09 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that it’s partnering with OTN Systems to address key connectivity challenges for industrial applications. The companies are teaming up to offer joint end-to-end networking solutions built with best-in-class technology and specifically designed for the industry sector. Now customers in transportation, oil and gas, mining and electrical power utilities can smoothly transition from their legacy SONET/SDH infrastructure and realize the benefits of packet transport. Featuring OTN Systems’ XTran MPLS-TP layer combined with ADVA FSP 3000 OLS technology, the tailor-made solutions are ruggedized for the harshest environments. They also provide stringent synchronization and comprehensive in-service monitoring, ensuring the levels of availability needed for the most advanced industrial demands.
”By joining forces with ADVA, we’re giving customers the full benefits of our combined innovation and expertise. Our companies share a goal of helping all industries on their digital transformation journeys. By delivering integrated end-to-end networks that precisely meet sector-specific requirements, we’re empowering our customers to take that next step,” said Jurgen Michielsen, CTO, OTN Systems. “From transportation to electric utilities, today’s industrial networks operators are looking for a seamless way to evolve their old SONET/SDH infrastructure to high-capacity packet-based network technology. The joint solution allows customers to make the jump to the next generation of telecom architecture simple, risk-free and extremely cost-effective.”
To keep pace with the demands of new applications, industrial networks must deliver greater bandwidth and improved quality of service. They need technology that supports an easy transition from increasingly obsolete SONET/SDH networks to packet-optical transport architectures. That’s precisely what ADVA and OTN Systems’ joint solutions provide. They enable operational infrastructure to cater for ever-increasing amounts of data traffic and support industrial automation. The combined solutions include the ADVA FSP 3000 OLS, which efficiently transports wavelengths over long distances using multiplexing, amplification, dispersion compensation, power leveling and wavelength routing. This is combined with OTN Systems’ XTran multi-service MPLS-TP platform designed for industrial applications. Growing security threats are also addressed with the protection of ADVA FSP 3000 ConnectGuard™ Optical encryption as well as strict synchronization needs with ADVA’s Oscilloquartz portfolio.
“We’re teaming up with OTN Systems to deliver industrial connectivity with a unique set of benefits. Together we can provide the most reliable and secure end-to-end networking solutions on the market – solutions that are fully optimized for next-generation industrial applications and specifically designed to withstand the most extreme environments,” commented Christoph Glingener, CTO, ADVA. “Our FSP 3000 enables industrial networks to minimize both cost per bit and operational efforts. Our joint customers can also further enhance performance and reduce operating costs with our ADVA ALM fiber monitoring solution. This gives industrial network operators full control with real-time insight into the fiber plant. What’s more, our Oscilloquartz technology range ensures the precise synchronization needed for ultra-low latency use cases.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
About OTN Systems
OTN systems is a leading supplier of mission-critical telecommunication solutions to industrial customers for more than 30 years. The company has developed a unique next generation platform tailored for industrial applications. XTran is a flexible, state-of-the-art product allowing customers to go full packet. Its underlying MPLS-TP technology avoids the complexity of generic telecom solutions developed for service providers. XTran secures reliable operations in a harsh environments, while its management system (TXCare) supports an intuitive and simple handling. Since its market introduction back in 2014, more than 100 customers worldwide have deployed XTran. For more information on our product and services offering, please visit us at www.otnsystems.com
, allowing you to fully appreciate how “we make MPLS for Operational Telecom easy.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20200714005053/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom